SHR4640

Phase 2Small molecule

JJiangsu HengRui Medicine Co., Ltd.

SHR4640 is one of 66 small molecule programs targeting Hyperuricemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaActive, not recruiting

Renal InsufficiencyActive, not recruiting

HyperuricemiaPhase 2

Active, not recruiting

Renal InsufficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

119 competitors in Renal Insufficiency

#DrugCompanyPhaseTrials

Galvus

Novartis

Phase 3

4 2

Afinitor

Novartis

Phase 3

1 3

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 5

Calcineurin Inhibitors

Sanofi

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 2

1 7

Velcade

SShilpa Grover, MD, MPH

Phase 2

2 8

Decadron

AAspen Global Incorporated

Phase 2

2 9

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 10

Tuoyi

CCoherus Oncology, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Hyperuricemia

NCT07362355

Clinical

Trials by Indication[1]

Hyperuricemia5 trials

The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07362355·340 enrolled

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03185793·198 enrolled

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04157959·28 enrolled

Show 2 more trials

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04180982·84 enrolled

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05513976·129 enrolled

Oral2 trials

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06168929·34 enrolled

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04620408·14 enrolled

Single Dose2 trials

Single Dose Study of SHR4640 in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02815839·50 enrolled

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Completed·AAtridia Pty Ltd.·Phase 1·NCT03015948·40 enrolled

Interaction2 trials

Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04850638·18 enrolled

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03131583·15 enrolled

Efficacy and Safety2 trials

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04052932·594 enrolled

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04956432·779 enrolled

6 more indications

ESS1 trial

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04586803·24 enrolled

Uric Acid1 trial

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Completed·AAtridia Pty Ltd.·Phase 1·NCT03211403·24 enrolled

Renal insufficiency1 trial

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05954169·16 enrolled

Hepatic Impairment1 trial

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04305392·24 enrolled

Adult1 trial

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04260373·6 enrolled

Unspecified1 trial

Multiple Dose Study of SHR4640 in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02890966·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for SHR4640. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR4640 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR4640. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

SHR4640

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hyperuricemia5 trials

Oral2 trials

Single Dose2 trials

Interaction2 trials

Efficacy and Safety2 trials

ESS1 trial

Uric Acid1 trial

Renal insufficiency1 trial

Hepatic Impairment1 trial

Adult1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News